The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 10000 participants.
Also called NCT06383390
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 10,000 participants
- Sponsor
- Registry
-
NCT06383390
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Türkiye, Ukraine, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06383390. Randomized; double masking; primary purpose treatment. Start 2024-04-30 (actual); primary completion 2029-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06383390- Content hash
cc64c1ff81156cb3914dd064ee0556d168ff47b63b4505814cbfbe08d2ae7f20